BIP Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==BIP Trial== * This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events. * ..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Obejective== | ||
* This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events. | * This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events. | ||
==Results== | |||
* Bezafibrate raised the [[HDL]] levels and decreased the [[triglyceride]] levels in patients with a previous [[myocardial infarction]] or [[stable angina]]. An overall reduction in the risk of cardiovascular events was noted.<ref name="pmid10880410">{{cite journal |author= |title=Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study |journal=[[Circulation]] |volume=102 |issue=1 |pages=21–7 |year=2000 |month=July |pmid=10880410 |doi= |url=}}</ref> | * Bezafibrate raised the [[HDL]] levels and decreased the [[triglyceride]] levels in patients with a previous [[myocardial infarction]] or [[stable angina]]. An overall reduction in the risk of cardiovascular events was noted.<ref name="pmid10880410">{{cite journal |author= |title=Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study |journal=[[Circulation]] |volume=102 |issue=1 |pages=21–7 |year=2000 |month=July |pmid=10880410 |doi= |url=}}</ref> | ||
| Line 13: | Line 15: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:29, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
BIP Trial On the Web |
|
American Roentgen Ray Society Images of BIP Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Obejective
- This double blinded clinical trial studied the effects of bezafibrate on incidence of cardiovascular events.
Results
- Bezafibrate raised the HDL levels and decreased the triglyceride levels in patients with a previous myocardial infarction or stable angina. An overall reduction in the risk of cardiovascular events was noted.[1]
References
- ↑ "Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study". Circulation. 102 (1): 21–7. 2000. PMID 10880410. Unknown parameter
|month=ignored (help)